Consensus Thermo Fisher Scientific, Inc.
Stocks
TMO
US8835561023
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 475.66 USD | -1.32% |
|
-1.32% | -17.91% |
| 06-11 | Piper Sandler Initiates Thermo Fisher Scientific at Neutral With $510 Price Target | MT |
| 06-10 | Wall Street's Problem Is Not Just Inflation |  |
Evolution of the Average Target: Thermo Fisher Scientific, Inc.
Evolution of the Target Price: Thermo Fisher Scientific, Inc.
Changes in Analyst Recommendations: Thermo Fisher Scientific, Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +25.97% | |||||
| +36.9% | |||||
| +34.05% | |||||
| +65.71% | |||||
| +13.02% | |||||
| +44.11% | |||||
| +23.78% | |||||
| +11.27% | |||||
| +23.58% | |||||
| +40.65% | |||||
| Average | +31.90% | |||||
| Weighted average by Cap. | +33.12% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Piper Sandler | |
| HSBC | |
| Argus | |
| Morgan Stanley | |
| Stifel Nicolaus | |
| Leerink Partners | |
| JPMorgan Chase | |
| Jefferies & Co. | |
| Goldman Sachs | |
| Baird | |
| Barclays | |
| TD Cowen | |
| Evercore ISI | |
| UBS | |
| Raymond James | |
| Deutsche Bank Securities | |
| Citigroup | |
| Rothschild & Co Redburn | |
| Wells Fargo Securities | |
| KeyBanc Capital Markets | |
| Wolfe Research | |
| BofA Securities | |
| RBC Capital Markets | |
| William Blair & Co. | |
| Bernstein | |
| Scotiabank | |
| Redburn Atlantic | |
| Stephens Inc. | |
| Nephron Research | |
| CMB International | |
| ARC Independent Research | |
| China Merchants | |
| Atlantic Equities | |
| Morningstar | |
| Credit Suisse | |
| Cowen | |
| SVB Securities LLC | |
| SVB Leerink | |
| BTIG | |
| Benchmark Capital | |
| J.P. Morgan Chase |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TMO Stock
- Consensus Thermo Fisher Scientific, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition